When should a Mounjaro or Ozempic dose be increased?

The short answer

Evidence tier: 1 — the escalation rules are quoted from the current FDA prescribing information for Zepbound, Mounjaro, Wegovy and Ozempic; the dose-response figures come from randomised phase 3 trials.

No GLP-1 label puts dose increases on a timetable. Each label sets a floor of at least 4 weeks per step, and beyond that it allows an increase depending on response and tolerability. For tirzepatide (Mounjaro, Zepbound), the only step the weight label treats as routine is leaving 2.5 mg, which is a starting dose. After that, 5, 10 and 15 mg are all labeled maintenance doses.

The main points:

• Four weeks is a minimum, not a deadline. Prescribers often hold a dose for longer.
• Higher doses add average weight loss, but less at each step, while side effects climb.
• Hunger returning before the next shot has a pharmacokinetic explanation and does not by itself mean the dose has failed.
• Staying on a lower dose that works is a choice the labels support.

Moving up is a decision to make with your prescriber; this page explains what they weigh. The full ladders are in our GLP-1 titration schedule guide and the tirzepatide dosing schedule.

What do the labels say about when to increase the dose?

Evidence tier: 1 — wording quoted from section 2 of each FDA label (Zepbound and Mounjaro revised 08/2026, Wegovy 06/2026, Ozempic 05/2026).

All four labels start low, require at least 4 weeks per step and allow a step up only for a reason. They differ on what counts as a reason.

Three label sentences do most of the work:

• Zepbound: "Consider treatment response and tolerability when selecting the maintenance dosage. If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage."
• Wegovy: "If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks."
• Wegovy 7.2 mg: "For patients who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated, the dosage may be increased to a maximum dosage of 7.2 mg."

So "when to increase Ozempic dose" has a narrow label answer: Ozempic is a diabetes medicine, and each step above 0.5 mg is tied to glucose control, not weight.

Do higher doses lead to more weight loss?

Evidence tier: 1 — randomised, placebo-controlled phase 3 trials (SURMOUNT-1, STEP UP); the retatrutide figures are from a phase 2 trial of an unapproved drug.

Yes, on average, but the gain tapers off. SURMOUNT-1 randomised 2,539 adults without diabetes to fixed tirzepatide doses for 72 weeks, with a 20-week escalation period (Jastreboff et al., 2022):

Moving from 5 mg to 10 mg added about 4.5 percentage points on average. Moving from 10 mg to 15 mg added about 1.4. For semaglutide, STEP UP compared 7.2 mg with 2.4 mg over 72 weeks. The higher dose reached −18.7% against −15.6%, a difference of 3.1 points, but gastrointestinal adverse events rose from 61.2% to 70.8% and dysaesthesia (altered skin sensation) from 6.0% to 22.9% (Wharton et al., 2025).

Two cautions apply. These are averages: 85% of people on 5 mg in SURMOUNT-1 lost at least 5% of their weight. And participants were randomised to a dose, not escalated by response, so the trials do not test "moving up because hunger came back."

Unapproved retatrutide showed the same flattening curve in phase 2: −17.1% at 4 mg, −22.8% at 8 mg and −24.2% at 12 mg after 48 weeks (Jastreboff et al., 2023). It has no label or escalation rule (see the retatrutide profile).

Should I move up to 5 mg on Mounjaro?

Evidence tier: 1 — the Zepbound label defines 2.5 mg as an initiation dose and sets 5 mg as the first maintenance dose.

For weight management, this step has the clearest label answer. The Zepbound label says 2.5 mg "is for treatment initiation and is not approved as a maintenance dosage", and that "after 4 weeks, increase the dosage to 5 mg." The first month is a run-in that lets the gut adapt, not the treatment dose.

People ask because 2.5 mg is already working. That early response is real, but no trial tested 2.5 mg as a long-term weight dose, so nobody knows how well it holds up. The Mounjaro label for type 2 diabetes is worded differently. It ties increases to glucose control and does not describe 2.5 mg as initiation-only.

If 2.5 mg is causing troublesome side effects, the label's tolerability rule applies and timing becomes a conversation with the prescriber.

Should I stay at 7.5 mg or go up?

Evidence tier: 2 — the label wording is Tier 1, but no trial randomised people to stay at 7.5 mg against stepping up, so the trade-off is inferred.

The Zepbound label does not list 7.5 mg as a weight-management maintenance dose; those are 5, 10 and 15 mg. That does not make 7.5 mg unsafe or oblige anyone to move on, but there are no long-term weight trial data at 7.5 mg.

Prescribers looking at "stay or go up" usually weigh:

• Response. Is weight still falling, even slowly, and are health markers improving? Slowing after the first months is expected (see our plateau guide).
• Tolerability. Ongoing nausea, constipation, reflux or fatigue is a reason to wait; the labels support delaying a step.
• Goals. Someone near their target has less to gain from a higher dose than someone with far to go.
• Intake. If eating is already very low, a higher dose can make protein and fluid targets harder (see muscle loss on GLP-1s).

In SURMOUNT-1, the biggest average gain sat between 5 and 10 mg.

Why does hunger come back at the end of the week?

Evidence tier: 2 — the half-life and peak-time figures are from the labels' pharmacokinetics sections; linking the dip in drug level to appetite is a reasonable inference, not a trial finding.

Many people notice appetite or "food noise" returning in the last day or two before the next injection. The drug's kinetics explain why.

• Tirzepatide reaches its peak level about 24 hours after injection (range 8 to 72 hours). Its elimination half-life is "approximately 5-6 days", according to the Zepbound label.
• Semaglutide peaks 1 to 3 days after injection. Its half-life is "approximately 1 week", according to the Wegovy label.

With a half-life shorter than the dosing interval, tirzepatide levels fall noticeably between doses, so the end of the week is the low point. Semaglutide's profile is flatter, though people still report a dip. Steady state also takes time (4 weeks for tirzepatide, 4 to 5 weeks for semaglutide, per the labels), so the first weeks on a new dose are a poor guide.

What this means in practice:

• A late-week return of appetite is not proof the drug has "stopped working". It may simply be the trough.
• It is not automatically a reason to escalate. Prescribers may look first at meal structure, protein and fibre (see what to eat on a GLP-1) and at dose timing.
• Shortening the interval or splitting doses falls outside the labels, which set minimum gaps between doses. See our microdosing article.

For the separate question of whether response fades over months, see do GLP-1s stop working?

Is staying on a lower dose a legitimate choice?

Evidence tier: 1 — both the Zepbound and Wegovy labels list more than one maintenance dose and tell prescribers to weigh response and tolerability; SURMOUNT-1 tested 5 mg as a full treatment arm.

Yes. Zepbound lists three maintenance doses for weight and tells prescribers to consider a lower one if a dose is not tolerated. Wegovy lists 1.7 mg as well as 2.4 mg. In SURMOUNT-1, 5 mg was a full 72-week arm with a mean loss of 15%.

A lower dose may suit some people better:

• Fewer side effects. Adverse-event discontinuation in SURMOUNT-1 was 4.3% at 5 mg against 6.2–7.1% at the higher doses.
• Sustainability. Weight returns when treatment stops, so a dose someone can sustain for years matters more than the fastest loss (see stopping a GLP-1).

The exception is tirzepatide's 2.5 mg starting dose.

What do users report?

Evidence tier: 4 — counts come from our anonymised Reddit dataset using keyword matching; they show what people discuss, not what works.

We took GLP-1 posts from the site's Reddit dataset (tagged tirzepatide, semaglutide or retatrutide, or posted in r/Mounjaro, r/Semaglutide or r/Retatrutide): 2,643 deduplicated posts from 8 June to 5 November 2026. Keyword patterns for moving up, titrating or "staying at" a dose matched 532 posts (about 20%): 372 tagged tirzepatide, 129 semaglutide and 100 retatrutide (some carry several tags).

Within those 532 posts:

• 220 (41%) also mentioned side effects such as nausea, constipation or fatigue, usually weighing a step up against existing symptoms.
• 98 (18%) mentioned a stall or plateau as the reason for asking.
• 86 (16%) mentioned "food noise". 46 (9%) described appetite returning or the dose "wearing off" late in the week or before the next shot.
• 71 (13%) described choosing to stay at a current dose.
• 183 mentioned 5 mg and 108 mentioned 7.5 mg.

Keyword matching is approximate. Methodology is in our community insights article.

Limitations

This is educational content, not medical advice or a dosing plan.

• Labels were read from manufacturer copies matched to Drugs@FDA entries; we could not open the FDA-hosted PDFs, and newer supplements may change the wording.
• Trial figures come from published abstracts, and the trials used fixed doses, not response-guided escalation.
• The late-week hunger explanation is an inference; we found no trial measuring appetite across the dosing week.
• Reddit counts are keyword-based, self-selected and unverified.
• Reviewed by Marko Maal, MSc Pharmacy. Reviewer attribution does not create a clinician-patient relationship.

The bottom line

The labels for tirzepatide and semaglutide set limits, not a timetable. Each step needs at least 4 weeks, and moving up depends on response and tolerability. The one clear label-driven step for weight is leaving tirzepatide's 2.5 mg starting dose. After that, 5, 10 and 15 mg are all legitimate places to stay. Higher doses add weight loss on average, but less at each step, and side effects rise. Hunger creeping back late in the week usually reflects falling drug levels rather than failure. Bring response, side effects, goals and eating patterns to your prescriber, and decide together.

Related on this site

• Tirzepatide profile
• Semaglutide profile
• GLP-1 titration schedules
• Tirzepatide dosing schedule 2026
• What comes after the top GLP-1 dose
• GLP-1 weight-loss plateau
• Do GLP-1s stop working?
• Switching between GLP-1s
• GLP-1 side effects and how to manage them

References

• US Food and Drug Administration (Drugs@FDA). Zepbound (tirzepatide) injection, NDA 217806: prescribing information (revised 08/2026; text read from the manufacturer copy at pi.lilly.com).
• US Food and Drug Administration (Drugs@FDA). Mounjaro (tirzepatide) injection, NDA 215866: prescribing information (revised 08/2026; text read from the manufacturer copy at pi.lilly.com).
• US Food and Drug Administration (Drugs@FDA). Wegovy (semaglutide) injection and tablets, NDA 215256: prescribing information (revised 06/2026; text read from the manufacturer copy at novo-pi.com).
• US Food and Drug Administration (Drugs@FDA). Ozempic (semaglutide) injection, NDA 209637: prescribing information (revised 05/2026; text read from the manufacturer copy at novo-pi.com).
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. 2022. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 387(3):205-216. PMID 35658024 · doi:10.1056/NEJMoa2206038
• Wharton S, Freitas P, Hjelmesæth J, et al. 2025. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 13(11):949-963. PMID 40961952 · doi:10.1016/S2213-8587(25)00226-800226-8)
• Jastreboff AM, Kaplan LM, Frías JP, et al. 2023. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 389(6):514-526. PMID 37366315 · doi:10.1056/NEJMoa2301972
• MyPeptideStory Reddit signal dataset, GLP-1 subset (n=2,643 deduplicated posts, 8 June to 5 November 2026). Anonymised; methodology at peptide community insights.